Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer

BMC Systems Biology

Volumn 7, Issue SUPPL 5, 2013, Pages

  Udyavar, Akshata R ^a,b   Hoeksema, Megan D ^b   Clark, Jonathan E ^a   Zou, Yong ^b   Tang, Zuojian ^d   Li, Zhiguo ^d   Li, Ming ^b   Chen, Heidi ^b   Statnikov, Alexander ^d,e   Shyr, Yu ^b   Liebler, Daniel C ^a   Field, John ^f   Eisenberg, Rosana ^b   Estrada, Lourdes ^a,b   Massion, Pierre P ^a,b,c   Quaranta, Vito ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Veterans Affairs Hospitals   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Co expression network; FYN; gene expression; proteomics; RNAseq; Small cell lung cancer; SYK

Indexed keywords

ONCOPROTEIN; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENE SILENCING; GENETICS; HUMAN; LUNG SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEOMICS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS; PROTEIN-TYROSINE KINASES; PROTEOMICS; SMALL CELL LUNG CARCINOMA;

EID: 84889655850     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-7-S5-S1     Document Type: Article

References (81)

1. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Annals of Oncology 2006, 17:ii5-ii10.
2. Ettinger DS. Changing Face of Small-Cell Lung Cancer: Real and Artifact. Journal of Clinical Oncology 2006, 24:4526-4527. 10.1200/JCO.2006.07.3841, 17008688.
3. Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, Antonchick AP, Vintonyak VV, Schneider PM, Ninomiya T, Waldmann H, Büttner R, Rauh D, Heukamp LC, Thomas RK. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences 2012, 109:17034-17039.
4. Staaf J, Isaksson S, Karlsson A, Jönsson M, Johansson L, Jönsson P, Botling J, Micke P, Baldetorp B, Planck M. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer 2012, 132:2020-2031.
5. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1110. 10.1038/ng.2396, 22941188.
6. Horváth S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel PS. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 2006, 103:17402-17407. 10.1073/pnas.0608396103, 1635024, 17090670.
7. Shi Z, Derow CK, Zhang B. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression. BMC Systems Biology 2010, 4:74. 10.1186/1752-0509-4-74, 2902438, 20507583.
8. Winden KD, Oldham MC, Mirnics K, Ebert PJ, Swan CH, Levitt P, Rubenstein JL, Horvath S, Geschwind DH. The organization of the transcriptional network in specific neuronal classes. Molecular Systems Biology 2009, 5:291. 2724976, 19638972.
9. Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos GG, Geddert H, Schwalen A, Gabbert HE, Haeseler von A, Pitschke G, Schott M, Kronenwett R, Haas R, Rohr U-P. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 2008, 6:69. 10.1186/1479-5876-6-69, 2613386, 18992152.
10. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C, Zirlik K. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. Cancer Research 2009, 69:5424-5432. 10.1158/0008-5472.CAN-08-4252, 19549911.
11. Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger RJ, Elela SA. Alternative splicing of SYK regulates mitosis and cell survival. Nature Publishing Group 2011, 18:673-679.
12. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K. Proteomic and Genetic Approaches Identify Syk as an AML Target. Cancer Cell 2009, 16:281-294. 10.1016/j.ccr.2009.08.018, 2803063, 19800574.
13. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120:1175-1184. 10.1182/blood-2012-02-362624, 3418714, 22715122.
14. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237. 10.1182/blood-2007-07-100115, 2234057, 18006696.
15. Mócsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nature Publishing Group 2010, 10:387-402.
16. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nature Immunology 2002, 3:1129-1134. 10.1038/ni1202-1129, 12447370.
17. Takano T, Sada K, Yamamura H. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells. Antioxidants & Redox Signaling 2002, 4:533-541.
18. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118:6342-6352. 10.1182/blood-2011-02-333773, 22025527.
19. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585. 10.1182/blood-2009-08-236471, 2852362, 19965662.
20. Buttigieg J, Pan J, Yeger H, Cutz E. NOX2 (gp91phox) is a predominant O2 sensor in a human airway chemoreceptor cell line: biochemical, molecular, and electrophysiological evidence. AJP: Lung Cellular and Molecular Physiology 2012, 303:L598-L607. 10.1152/ajplung.00170.2012, 3469588, 22865553.
21. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Seminars in Oncology 2004, 31:4-19.
22. Levitt ML, Gazdar AF, Oie HK, Schuller H, Thacher SM. Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines. Cancer Research 1990, 50:120-128.
23. Dakir EH, Feigenbaum L, Linnoila RI. Constitutive expression of human keratin 14 gene in mouse lung induces premalignant lesions and squamous differentiation. Carcinogenesis 2008, 29:2377-2384.
24. Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Genetic changes in small cell lung carcinoma. Clin Transl Oncol 2008, 10:189-197. 10.1007/s12094-008-0181-1, 18411191.
25. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, Tanizawa T, Fujisawa T, Nakatani Y. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006, 19:1358-1368. 10.1038/modpathol.3800659, 16862075.
26. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001, 411:41-42. 10.1038/35075138, 11333967.
27. He X, Zhang J. Why Do Hubs Tend to Be Essential in Protein Networks?. PLoS Genet 2006, 2:e88. 10.1371/journal.pgen.0020088, 1473040, 16751849.
28. Dutta B, Pusztai L, Qi Y, eacute FA, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, zsi GBA. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. British Journal of Cancer 2012, 1-10.
29. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9:559. 10.1186/1471-2105-9-559, 2631488, 19114008.
30. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. Journal of Clinical Oncology 2006, 24:1679-1688. 10.1200/JCO.2005.03.8224, 16549822.
31. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Nomura H, Ishikawa Y. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004, 363:775-781. 10.1016/S0140-6736(04)15693-6, 15016488.
32. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, Falk R, Travis WD. Small Cell Lung Carcinoma (SCLC) - A Clinicopathologic Study of 100 Cases With Surgical Specimens. The American Journal of Surgical Pathology 2002, 26:1184-1197. 10.1097/00000478-200209000-00009, 12218575.
33. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Research 2005, 33(Web Server):W741-8. 10.1093/nar/gki475, 1160236, 15980575.
34. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discovery Today 2010, 15:517-530. 10.1016/j.drudis.2010.05.001, 20553955.
35. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn - A Novel Molecular Target in Cancer. Cancer 2010, 116:1629-1637. 10.1002/cncr.24879, 2847065, 20151426.
36. Lockwood WW, Chari R, Coe BP, Girard L, MacAulay C, Lam S, Gazdar AF, Minna JD, Lam WL. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008, 27:4615-4624. 10.1038/onc.2008.98, 2849646, 18391978.
37. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. Journal of Biochemistry 2001, 130:177-186. 10.1093/oxfordjournals.jbchem.a002970, 11481033.
38. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 2012, 8:e1002375. 10.1371/journal.pcbi.1002375, 3285573, 22383865.
39. Subramanian J, Simon R. Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?. JNCI Journal of the National Cancer Institute 2010, 102:464-474.
40. Renshaw AA, Voytek TM, Haja J, Wilbur DC, , Cytology Committee, College of American Pathologists Distinguishing small cell carcinoma from non-small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. 2005, 129:619-623. Cytology Committee, College of American Pathologists.
41. Rekhtman N. Neuroendocrine Tumors of the Lung: An Update. Arch Pathol Lab Med 2010, 134:1628-1638.
42. Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 2008, 111:2904-2908. 10.1182/blood-2007-05-091769, 2254539, 18180382.
43. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, et A. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334. 3289956, 22237022.
44. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Research 2009, 69:6889-6898. 10.1158/0008-5472.CAN-09-0347, 2770839, 19690143.
45. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYNis overexpressed in human prostate cancer. BJU International 2009, 103:171-177. 10.1111/j.1464-410X.2008.08009.x, 2741693, 18990162.
46. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proceedings of the National Academy of Sciences 2011, 108:6579-6584.
47. SADA K, MINAMI Y, YAMAMURA H. Relocation of Syk Protein-Tyrosine Kinase to the Actin Filament Network and Subsequent Association with Fak. Eur J Biochem 1997, 248:827-833. 10.1111/j.1432-1033.1997.00827.x, 9342235.
48. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909. 10.1038/sj.onc.1208160, 15489908.
49. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 2010, 29:6331-6342. 10.1038/onc.2010.362, 20802517.
50. Ocak S, Chen H, Callison C, Gonzalez AL, Massion PP. Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer 2011, 118:1293-1301. 3673887, 21800286.
51. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995, 378:303-306. 10.1038/378303a0, 7477353.
52. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000, 406:742-747.
53. Coopman PJ, Mueller SC. The Syk tyrosine kinase: A new negative regulator in tumor growth and progression. Cancer Letters 2006, 241:159-173. 10.1016/j.canlet.2005.11.004, 16442709.
54. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2013, 483:603-307.
55. Garnett MJ, Garnett MJ, Edelman EJ, Edelman EJ, Heidorn SJ, Heidorn SJ, Greenman CD, Greenman CD, Dastur A, Dastur A, Lau KW, Lau KW, Greninger P, Greninger P, Thompson IR, Thompson IR, Luo X, Luo X, Soares J, Soares J, Liu Q, Liu Q, Iorio F, Iorio F, Surdez D, Surdez D, Chen L, Chen L, Milano RJ, Milano RJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575. 10.1038/nature11005, 3349233, 22460902.
56. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19:754-764. 10.1016/j.ccr.2011.04.019, 21665149.
57. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research 2009, 69:3364-3373. 10.1158/0008-5472.CAN-08-4210, 2821899, 19351829.
58. Kuno Y. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001, 97:1050-1055. 10.1182/blood.V97.4.1050, 11159536.
59. Rigby S, Huang Y, Streubel B, Chott A, Du MQ, Turner SD, Bacon CM. The Lymphoma-associated Fusion Tyrosine Kinase ITK-SYK Requires Pleckstrin Homology Domain-mediated Membrane Localization for Activation and Cellular Transformation. Journal of Biological Chemistry 2009, 284:26871-26881. 10.1074/jbc.M109.034272, 2785375, 19535334.
60. Yuan Y, Mendez R, Sahin A, Le Dai J. Hypermethylation Leads to Silencing of the SYK Gene in Human Breast Cancer. Cancer Research 2001, 61:5558-5561.
61. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discovery 2012, 2:798-811. 10.1158/2159-8290.CD-12-0112, 3567922, 22961666.
62. Hirsch F, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier A, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar A, Crino L, Gandara D, Franklin W, Bunn P. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology 2006, 18:752-760.
63. Hirsch FR. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology 2003, 21:3798-3807. 10.1200/JCO.2003.11.069, 12953099.
64. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Holko M, Ayanbule O, Yefanov A, Soboleva A. NCBI GEO: archive for functional genomics data sets--10 years on. Nucleic Acids Research 2010, 39(Database):D1005-D1010. 3013736, 21097893.
65. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315. 10.1093/bioinformatics/btg405, 14960456.
66. Team RC. R: a Language and Environment for Statistical Computing 2012, Vienna, Austria.
67. Chu L, Eric S, Kondo T. GeneSpring: Tools for Analyzing Microarray Expression Data. Genome Informatics 2001, 12:227-229.
68. Miller JA, Cai C, Langfelder P, Geschwind DH, Kurian SM, Salomon DR, Horvath S. Strategies for aggregating gene expression data: The collapseRows R function. BMC Bioinformatics 2011, 12:322. 10.1186/1471-2105-12-322, 3166942, 21816037.
69. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006, 22:1540-1542. 10.1093/bioinformatics/btl117, 16595560.
70. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Liaw WHA, Lumley T, Maechler M, Magnusson A, Moeller S, Schwartz M, Venables B. Gplots: Various R Programming Tools for Plotting Data 2012,
71. Statnikov A, Tsamardinos I, Dosbayev Y, Aliferis CF. GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data. Int J Med Inform 2005, 74:491-503. 10.1016/j.ijmedinf.2005.05.002, 15967710.
72. Benjamini Y, Hochberg Y. Controlling the false discovery rate- a practical and powerful approach to multiple testing. J R Statist Soc Series B (Methodological) 1995, 57:289-300.
73. Sprung RW, Brock JWC, Tanksley JP, Li M, Washington MK, Slebos RJC, Liebler DC. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics 2009, 8:1988-1998. 10.1074/mcp.M800518-MCP200, 2722776, 19467989.
74. Slebos RJC, Brock JWC, Winters NF, Stuart SR, Martinez MA, Li M, Chambers MC, Zimmerman LJ, Ham AJ, Tabb DL, Liebler DC. Evaluation of strong cation exchange versus isoelectric focusing of peptides for multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 2008, 7:5286-5294. 10.1021/pr8004666, 2669493, 18939861.
75. Ma ZQ, Dasari S, Chambers MC, Litton MD, Sobecki SM, Zimmerman LJ, Halvey PJ, Schilling B, Drake PM, Gibson BW, Tabb DL. IDPicker 2.0: Improved protein assembly with high discrimination peptide identification filtering. J Proteome Res 2009, 8:3872-3881. 10.1021/pr900360j, 2810655, 19522537.
76. Ma ZQ, Tabb DL, Burden J, Chambers MC, Cox MB, Cantrell MJ, Ham AJL, Litton MD, Oreto MR, Schultz WC, Sobecki SM, Tsui TY, Wernke GR, Liebler DC. Supporting tool suite for production proteomics. Bioinformatics 2011, 27:3214-3215. 10.1093/bioinformatics/btr544, 3208394, 21965817.
77. Tabb DL, Fernando CG, Chambers MC. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J Proteome Res 2007, 6:654-661. 10.1021/pr0604054, 2525619, 17269722.
78. Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, Shyr Y, Slebos RJC. Comparative Shotgun Proteomics Using Spectral Count Data and Quasi-Likelihood Modeling. J Proteome Res 2010, 9:4295-4305. 10.1021/pr100527g, 2920032, 20586475.
79. Kutner MH. Applied Linear Statistical Models 2005, McGraw-Hill Education.
80. Kuehl RO. Design of Experiments 2000, Duxbury Press.
81. Kruskal WH, Wallis WA. Use of Ranks in One-Criterion Variance Analysis. Journal of the American Statistical Association 1952, 47:583-621.